source
- Bolt Biotherapeutics to acquire Prana Therapies in reverse merger, secured $120M financingBolt Biotherapeutics announced a stock‑for‑stock reverse merger with Prana Therapies. The transaction is supported by a $120 million financing package. The deal will bring Prana’s lead antibody in…
- Alnylam to launch larger study of RNA therapy for Huntington’s diseaseAlnylam Therapeutics announced it will expand its clinical program for an RNA‑based drug aimed at treating Huntington’s disease. The decision comes amid a challenging landscape for neurodegenerati…